Cell Wall News and Research

RSS

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

Researchers identify genetic mechanisms involved in the formation and survival of L-form bacteria

Researchers at the Johns Hopkins Bloomberg School of Public Health have for the first time identified the genetic mechanisms involved in the formation and survival of L-form bacteria. Their findings are described in a study published October 6 in the journal PLoS ONE.

14 Oct 2009

Development of lab-on-chip system for breast cancer detection and therapy

IMEC, a leading European research center in nanotechnology, the Institüt für Mikrotechnik Mainz (IMM), one of the leading European research centers in microfluidics, and their partners within the European Sixth Framework Project MASCOT achieve a major milestone in the development of a lab-on-chip for the detection and therapy evaluation of breast cancer.

8 Oct 2009

Research finds novel chemical that targets drug-resistant bacteria

Eric Brown, a professor and chair of the Department of Biochemistry and Biomedical Sciences, and a team of researchers from the Michael G. DeGroote Institute for Infectious Disease Research have identified a novel chemical compound that targets drug-resistant bacteria in a different way from existing antibiotics. The discovery could lead to new treatments to overcome antibiotic resistance in certain types of microorganisms.

29 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

Bioniche announces fiscal 2009 year-end results

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

19 Sep 2009

Microbe's multilayer defence mechanisms could treat fungal infections

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

8 Sep 2009

Manuka honey inhibits MRSA infections by killing bacterial proteins

Manuka honey may kill bacteria by destroying key bacterial proteins. Dr Rowena Jenkins and colleagues from the University of Wales Institute - Cardiff investigated the mechanisms of manuka honey action and found that its anti-bacterial properties were not due solely to the sugars present in the honey.

7 Sep 2009

Urine LAM-ELISA's sensitivity of 50.7% in identifying TB disappoints

Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis (TB). A trial of the new diagnostic, described in the open access journal BMC Infectious Diseases found that it was only capable of identifying 50.7% of TB cases.

28 Aug 2009

Clever biochemical strategy enables bacteria to move freely and colonize host

A team of researchers from Boston University, Harvard Medical School and Massachusetts Institute of Technology recently made a discovery that changes a long held paradigm about how bacteria move through soft gels.

13 Aug 2009

New tuberculosis drug targets

A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis.

23 Jun 2009

New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes

A synthetic DNA binding compound has proved surprisingly effective at binding to the DNA of bacteria and killing all the bacteria it touched within two minutes.

8 Jun 2009

Discovery of two proteins may lead to more effective treatment of endocarditis and infections associated with implants

A research team at the Faculty of Odontology at Malmö University in Sweden has discovered two new proteins that are of importance to the survival of bacteria and their colonization of the human body. Besides enhancing our knowledge of the ability of bacteria to spread, the findings may also lead to more effective treatment of endocarditis and infections associated with implants.

4 Jun 2009

New therapy shows potential for treating Duchenne muscular dystrophy

Researchers at the University of Minnesota Medical School have discovered a new therapy that shows potential to treat people with Duchenne muscular dystrophy, a fatal disease and the most common form of muscular dystrophy in children.

26 May 2009

Researchers discover six new genome sequences and fundamental insights to the Candida fungus family

An international research collaboration coordinated by UCD researchers and involving scientists at 21 institutes including the genome sequencing centres in the Wellcome Trust Sanger Institute, UK and the Broad Institute at MIT and Harvard, USA have defined six new genome sequences in the Candida fungus family and identified genetic differences in species that cause disease.

25 May 2009

Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).

25 May 2009

New understanding on how superbugs manipulate the immune system

It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone's advantage.

24 May 2009

FDA strengthens safety of Sucraid (sacrosidase) oral solution

The U.S. Food and Drug Administration today issued an expedited approval of a supplemental application that allows for changes in the manufacturing of Sucraid (sacrosidase) Oral Solution.

20 Nov 2008

First-ever glimpse of the cell-wall structure in three dimensions

The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).

17 Nov 2008

New technology to control the motion of bacteria that produce cellulose - biomaterial and medical implant potential

Two Virginia Tech engineers have put bacteria to work as tiny weavers of biomaterials and medical implants.

11 Nov 2008